DE69523951D1 - Stabilisierung der prostaglandinzusammensetzungen - Google Patents

Stabilisierung der prostaglandinzusammensetzungen

Info

Publication number
DE69523951D1
DE69523951D1 DE69523951T DE69523951T DE69523951D1 DE 69523951 D1 DE69523951 D1 DE 69523951D1 DE 69523951 T DE69523951 T DE 69523951T DE 69523951 T DE69523951 T DE 69523951T DE 69523951 D1 DE69523951 D1 DE 69523951D1
Authority
DE
Germany
Prior art keywords
compositions
prostagland
stabilization
prostaglandin
chemical stability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69523951T
Other languages
English (en)
Other versions
DE69523951T2 (de
Inventor
Wayne Schneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Alcon Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23427079&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69523951(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Laboratories Inc filed Critical Alcon Laboratories Inc
Application granted granted Critical
Publication of DE69523951D1 publication Critical patent/DE69523951D1/de
Publication of DE69523951T2 publication Critical patent/DE69523951T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69523951T 1994-12-22 1995-12-19 Stabilisierung der prostaglandinzusammensetzungen Expired - Lifetime DE69523951T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/362,677 US5631287A (en) 1994-12-22 1994-12-22 Storage-stable prostaglandin compositions
PCT/US1995/017086 WO1997029752A1 (en) 1994-12-22 1995-12-19 Storage-stable prostaglandin compositions

Publications (2)

Publication Number Publication Date
DE69523951D1 true DE69523951D1 (de) 2001-12-20
DE69523951T2 DE69523951T2 (de) 2002-04-04

Family

ID=23427079

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69523951T Expired - Lifetime DE69523951T2 (de) 1994-12-22 1995-12-19 Stabilisierung der prostaglandinzusammensetzungen

Country Status (12)

Country Link
US (2) US5631287A (de)
EP (1) EP0812198B1 (de)
JP (3) JP3631255B2 (de)
AT (1) ATE208621T1 (de)
AU (1) AU700574B2 (de)
CA (1) CA2181172C (de)
DE (1) DE69523951T2 (de)
DK (1) DK0812198T3 (de)
ES (1) ES2162951T3 (de)
MX (1) MX9603560A (de)
PT (1) PT812198E (de)
WO (1) WO1997029752A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AR002194A1 (es) † 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
WO1998050024A1 (en) * 1997-05-09 1998-11-12 The Mount Sinai School Of Medicine Of The City University Of New York 8-iso-prostaglandins for glaucoma therapy
ATE285795T1 (de) * 1998-07-14 2005-01-15 Alcon Mfg Ltd Polypropylenbasierte behälter für prostaglandin- enthaltende produkte
US6235781B1 (en) 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
AR020661A1 (es) 1998-09-30 2002-05-22 Alcon Lab Inc Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
US7678836B2 (en) * 1999-11-04 2010-03-16 Fxs Ventures, Llc Method for rendering a contact lens wettable
US7166730B2 (en) * 2000-01-27 2007-01-23 Fine Tech Laboratories, Ltd Process for the preparation of prostaglandin derivatives
EP1321144B1 (de) * 2000-09-13 2010-12-08 Santen Pharmaceutical Co., Ltd. Augentropfen
US7816399B2 (en) 2001-04-19 2010-10-19 Teika Pharmaceutical Co., Ltd. Medicines and medicinal kits
US20060264353A1 (en) * 2002-03-21 2006-11-23 Maxey Kirk M Prostaglandin f2alpha analogs and their use in combination with antimicrobial proteins for the treatment of glaucoma and intraocular hypertension
US20040079671A1 (en) * 2002-08-29 2004-04-29 Paramita Bandyopadhyay Medicinal product packaging
AU2003261981A1 (en) * 2002-09-09 2004-03-29 Santen Pharmaceutical Co., Ltd. Transparent eye drops containing latanoprost
DE602004023106D1 (de) 2003-11-07 2009-10-22 Senju Pharma Co Pharmazeutische zusammensetzung mit prostaglandin
GB0329620D0 (en) * 2003-12-22 2004-01-28 Pharmagene Lab Ltd EP2 receptor agonists
PL1759702T3 (pl) * 2004-05-26 2009-06-30 Bayardo Arturo Jimenez Sposób wytwarzania roztworu latanoprostu do oczu oraz roztwór otrzymany tym sposobem
ATE412400T1 (de) * 2004-11-09 2008-11-15 Novagali Pharma Sa Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
WO2007015510A1 (ja) * 2005-08-02 2007-02-08 Santen Pharmaceutical Co., Ltd. 熱的に不安定な薬物の分解抑制方法
CN104224704A (zh) * 2006-03-13 2014-12-24 株式会社·R-技术上野 水性组合物
WO2007111806A2 (en) 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
US20080095863A1 (en) * 2006-10-24 2008-04-24 Alcon Manufacturing Ltd. 2-pyrrolidone derivatives for preservation of ophthalmic, otic and nasal compositions
EP2123278B1 (de) 2007-02-07 2013-01-09 Teika Pharmaceutical Co., Ltd. Augentropfenzubereitung mit latanoprost
EP1985298A1 (de) * 2007-04-24 2008-10-29 Azad Pharma AG Prostaglandinhaltige Öl-in-Wasser-Emulsionen für das Auge
WO2009084021A2 (en) * 2007-10-16 2009-07-09 Sun Pharma Advanced Research Company Limited Novel ophthalmic compositions
EP2077105A1 (de) 2008-01-02 2009-07-08 Novagali Pharma SA Ophthalmische mizellare Zusammensetzung mit erhöhter Stabilität
EP2077104A1 (de) 2008-01-02 2009-07-08 Novagali Pharma SA Mizellare Zusammensetzungen mit ophtalmischen Anwendungen
US20090232763A1 (en) 2008-03-17 2009-09-17 Kabra Bhagwati P Aqueous pharmaceutical compositions containing borate-polyol complexes
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
JP2009256281A (ja) * 2008-04-21 2009-11-05 Teika Seiyaku Kk イソプロピルウノプロストン含有点眼剤組成物
EP2127638A1 (de) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Verfahren und Zusammensetzung zur Behandlung von Augenhochdruck und Glaukom
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
EP2228058A1 (de) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionische Öl-in-Wasser-Emulsion mit Prostaglandinen und Verwendungen dafür
TWI489997B (zh) * 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物
EP2498768A1 (de) * 2009-11-11 2012-09-19 Micro Labs Limited Pharmazeutische kombination aus einer prostaglandinverbindung und nsaid zur behandlung von glaukom und augenhochdruck
EP2389939A1 (de) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Verwendung von Prostaglandinen F2alpha und Analoga zur Heilung von Horn- und Bindehautläsionen
FR2961694B1 (fr) 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
EP2452669A1 (de) 2010-10-29 2012-05-16 Omnivision GmbH Ophthalmische Zusammensetzung
JP2014500275A (ja) 2010-12-06 2014-01-09 フォリカ，インコーポレイテッド 禿頭症を治療するため、および毛髪の成長を促進するための方法
ES2687494T3 (es) 2011-01-19 2018-10-25 Topokine Therapeutics, Inc. Métodos y composiciones para reducir la grasa corporal
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
ITRM20120036A1 (it) * 2012-02-02 2013-08-03 Robert Davis Steigerwalt Jr Applicazione transdermica di prostaglandina e1 per il trattamento dell¿ischemia oculare.
CA2869676C (en) 2012-11-21 2015-06-23 Topokine Therapeutics, Inc. Uses and compositions comprising a thiazolidinedione and oleic acid for locally increasing subcutaneous fat
NO2753788T3 (de) 2013-05-10 2018-06-16
WO2014186504A1 (en) 2013-05-15 2014-11-20 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
TWI612960B (zh) * 2014-01-10 2018-02-01 Santen Pharmaceutical Co Ltd 吡啶基胺基乙酸化合物及含聚氧乙烯蓖麻油之醫藥組成物
AU2015205179B2 (en) 2014-01-10 2019-09-19 Santen Pharmaceutical Co., Ltd. Pharmaceutical composition containing pyridylamino acetic acid compound
WO2015200425A1 (en) 2014-06-27 2015-12-30 Topokine Therapeutics, Inc. Topical dosage regimen
CA2999988C (en) 2015-09-27 2024-06-11 Follica, Inc. Needling device and drug applicator
EP3883562A4 (de) 2018-11-21 2022-08-03 Tremeau Pharmaceuticals, Inc. Gereinigte formen von rofecoxib, verfahren zur herstellung und verwendung

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2526938C2 (de) * 1975-02-14 1982-04-22 F. Hoffmann-La Roche & Co. AG, 4002 Basel Vitaminpräparate
JPS6046094B2 (ja) * 1977-06-01 1985-10-14 科研製薬株式会社 安定化されたプロスタグランジンｅ類粉末製剤
JPS59216820A (ja) * 1983-05-20 1984-12-06 Taisho Pharmaceut Co Ltd プロスタグランジン脂肪乳剤
DE3347128A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 9-halogen-(delta)(pfeil hoch)2(pfeil hoch)-prostaglandinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3510978A1 (de) * 1985-03-22 1986-09-25 Schering AG, Berlin und Bergkamen, 1000 Berlin Neue 9-halogenprostaglandine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US5110493A (en) * 1987-09-11 1992-05-05 Syntex (U.S.A.) Inc. Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
JP2597629B2 (ja) * 1988-02-26 1997-04-09 株式会社 上野製薬応用研究所 １３，１４−ジヒドロ−１５−ケトプロスタグランジン類の安定化
US4960799A (en) * 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
JPH0669966B2 (ja) * 1989-07-05 1994-09-07 株式会社ミドリ十字 血管造影補助剤
JPH03101622A (ja) * 1989-09-11 1991-04-26 Green Cross Corp:The 肝炎予防治療剤
JP2785981B2 (ja) * 1989-11-20 1998-08-13 株式会社資生堂 乳化組成物
CA2031469A1 (en) * 1989-12-28 1991-06-29 Larry A. Wheeler Use of inclusion complexes of prostaglandins with cyclodextrins in the treatment of ocular hypertension
JP3256997B2 (ja) * 1990-08-30 2002-02-18 千寿製薬株式会社 安定な水性製剤
DE69311361T2 (de) * 1992-10-13 1998-01-08 Alcon Lab Inc Zusammensetzungen zur behandlung von glaukoma die prostaglandine und clonidinderivate enthalten
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
AU687906B2 (en) * 1993-12-15 1998-03-05 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension

Also Published As

Publication number Publication date
JP3631255B2 (ja) 2005-03-23
US5631287A (en) 1997-05-20
JPH11500122A (ja) 1999-01-06
US5849792A (en) 1998-12-15
JP2005015498A (ja) 2005-01-20
PT812198E (pt) 2002-02-28
JP2010043131A (ja) 2010-02-25
DE69523951T2 (de) 2002-04-04
MX9603560A (es) 1998-01-31
ES2162951T3 (es) 2002-01-16
AU4649596A (en) 1997-09-02
CA2181172A1 (en) 1996-06-23
CA2181172C (en) 2003-04-29
AU700574B2 (en) 1999-01-07
DK0812198T3 (da) 2002-03-18
ATE208621T1 (de) 2001-11-15
EP0812198A1 (de) 1997-12-17
EP0812198B1 (de) 2001-11-14
WO1997029752A1 (en) 1997-08-21

Similar Documents

Publication Publication Date Title
ATE208621T1 (de) Stabilisierung der prostaglandinzusammensetzungen
BR9916132A (pt) Composições e utilização das mesmas
ATE326983T1 (de) Aminoalkohole enthaltende ophthalmische zusammensetzungen
ES2138691T3 (es) Procedimiento para la obtencion de derivados de n-acil-5-fluorocitidina.
YU47204B (sh) Derivati didehidro-vitamina d3
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
PT758248E (pt) Formulacoes para o factor ix
FI931250A (fi) Sulfonamido- och sulfonamidokarbonyl-pyridin-2-karboxylsyraamider och deras pyridin-n-oxider, foerfarande foer deras framstaellning och deras anvaendning som laekemedel
ATE208208T1 (de) Halogenid-enthaltende insulinzubereitungen
BR9711586A (pt) Compostos e uso dos mesmo
ES2157992T3 (es) Alcoxi-alquil-carbamatos de imidazo(1,2-a)piridinas.
FR2681784B1 (fr) Composition dermatologique et/ou cosmetologique contenant des retinouides et utilisation de nouveaux retinouides.
HU9501801D0 (en) Lactame-compounds as pharmaceutical active component
ES2184774T3 (es) Bifenil-2,2'-diil-bis-difenilfosfinas halogenadas, su preparacion y empleo.
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
YU46914B (sh) Metoksimetilna jedinjenja
FI923751A0 (fi) Hexahydrobenso/f/kinolinoner.
CA2061995A1 (en) Use of oxime ether derivatives for bioregulation in plants
DE69208681D1 (de) Verwendungen von 1,1,1,3,3,3-hexafluoropropan
EA199700032A1 (ru) Дезинфицирующий состав "велтолен"
DE69813165D1 (de) Hautdepigmentierungsmittel
FI960588A0 (fi) Mikrobisideina käytettäviä tiokarbamoyyliyhdisteitä
ATE204286T1 (de) Modifizierte alpha-d-glcp-(1,2)-alpha-d-glcp-(1, 3)-alpha-d-glcp-analoge
DE69030635D1 (de) Verwendung von Prostacyclin-Analoga gegen Metastasen
TR199701011A2 (xx) 1-karba-(detia)-sefalosforin t�revleri.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition